



Alkalon Files for European Approval of Nicorono Nicotine Gum

Alkalon A/S has completed 2 years development work and now filed for regulatory approval of its new generic nicotine gum in a number of European countries anticipating commercial launch 2012.

COPENHAGEN, August 18, 2011. Alkalon today announced that it has filed for marketing approval of its generic nicotine gum for smoking cessation. Alkalon is seeking approval based on a clinical study that showed bioequivalence to the reference product Nicorette[®] nicotine gum.

Chief Executive Officer Mr. Bo Tandrup said: "During the coming year Alkalon's business focus will be international commercialisation of the dossiers primarily by entering license and supply agreements with generic companies Worldwide. Alkalon expects to start a new promising development project shortly and in the future we wish to be able to offer not only smoking cessation gums, but also products in other categories."

Managing Partner at SEED Capital Ulla Brockenhuus-Schack said: "Alkalon has developed a very competitive product and has already secured partnerships with some of the largest European distributors. We see this filing as an important milestone to bring a quality product to the world market and thereby help millions of people stop smoking."

About Alkalon

Alkalon is an independent, privately-owned contract research and product development company based in Denmark. The company specialises in the development of medicated chewing gum formulations and is working in partnership with pharmaceutical companies on dosage form development projects and the supply of finished products.